Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[3.]
Comisión de Regulación en Salud. Ministerio de Protección en Salud. Metodología para la actualización integral del Plan Obligatorio de Salud del Sistema General de Seguridad en Salud. Informe Técnico. Junio 2011, Bogotá, DC.
[4.]
H.D. Banta, C.J. Behney, J.S. Willems.
Toward Rational Technology in Medicine.
Springer Publ. Co, (1981),
[5.]
H.D. Banta, S.B. Thacker.
The case for reassessment of Health Care Technology: Once is not enough.
JAMA, 264 (1990), pp. 235-240
[6.]
M. Drummond, B. Obrien, G. Stoddart, G. Torrance.
Métodos para la Evaluación Económica de los Programas de Asistencia Sanitaria.
2a, Editorial Díaz de Santos, (2001),
[7.]
M. Drummond, A. Brandt, B. Luce, J. Rovira.
Standardizing Methodologies for economic evaluation in health care.
Int J Technol Assess Health Care, 9 (1993), pp. 26-36
[8.]
F. Najafi, K. Jamrozik, A.J. Dobson.
Understanding the “epidemic of heart failure”: a systematic review of trends in determinants of heart failure.
Eur J Heart Fail, 11 (2009), pp. 472-479
[9.]
G.F. Mendez, M.R. Cowie.
The epidemiological features of heart failure in developing countries; a review of the literature.
Int J Cardiol, 80 (2001), pp. 213-219
[10.]
M. Jessup, S. Brozena.
Heart failure.
N Engl J Med, 348 (2003), pp. 2007-2018
[11.]
T. Murray-Thomas, M.R. Cowie.
Epidemiology and clinical aspects of congestive heart failure.
J Renin Angiotensin Aldosterone Syst, 4 (2003), pp. 131-136
[12.]
A.R. Omran.
The epidemiologic transition: a theory of the epidemiology of population change.
Milbank Mem Fund Q, XLIX (1971), pp. 509-538
[13.]
P.W. Wilson.
An epidemiologic perspective of systemic hypertension, ischemic heart disease and heart failure.
Am J Cardiol, 80 (1997), pp. 3J-8J
[14.]
D.S. Hanes, M.R. Weir, J.R. Sowers.
Gender considerations in hypertension pathophysiology and treatment.
Am J Med, 101 (1996), pp. 10S-21S
[15.]
F. Waagstein, A. Hjalmarson, E. Varnauskas, I. Wallentin.
Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.
Br Heart J, 37 (1975), pp. 1022-1036
[16.]
K. Swedberg, A. Hjalmarson, F. Waagstein, I. Wallentin.
Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.
Lancet, 1 (1979), pp. 1374-1376
[17.]
J. Cosin Aguilar.
Hernández Martínez. Ensayos clínicos en Insuficiencia Cardíaca.
Rev Esp Cardiol, 54 (2001), pp. 22-31
[18.]
S.A. Hunt, W.T. Abraham, M.H. Chin.
Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult.
J Am Coll Cardiol, 46 (2005), pp. 1116-1143
[19.]
M.R. Bristow, R. Ginsburg, W. Minobe, et al.
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.
N Engl J Med, 307 (1982), pp. 205
[20.]
S.D. Prabhu, B. Chandrasekar, D.R. Murray, G.L. Freeman.
beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling.
Circulation, 101 (2000), pp. 2103
[21.]
Y. Lu, L. Li, X. Zhao, W. Huang, W. Wen.
Beta blocker metoprolol protects against contractile dysfunction in rats after coronary microembolization by regulating expression of myocardial inflammatory cytokines.
Life Sci, 88 (2011), pp. 1009-1015
[22.]
B.D. Lowes, E.M. Gilbert, W.T. Abraham, et al.
Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents.
N Engl J Med, 346 (2002), pp. 1357
[23.]
F. Waagstein, M.R. Bristow, K. Swedberg, F. Camerini, M.B. Fowler, M.A. Silver, Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, et al.
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.
Lancet, 342 (1993), pp. 1441-1446
[24.]
M. Packer, M. Bristow, J. Cohn, for the US carvedilold heart failure study group, et al.
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.
N Engl J Med, 334 (1996), pp. 1349-1355
[26.]
CIBIS–II., Investigators, Committees,.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial.
Lancet, 353 (1999), pp. 9-13
[27.]
MERIT–HF., Study, Group.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT–HF).
Lancet, 353 (1999), pp. 2001-2007
[28.]
A. Jost, B. Rauch, M. Hochadel, et al.
Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study.
Eur Heart J, 26 (2005), pp. 2689-2697
[29.]
M. Packer, A. Coats, M. Fowler, et al.
Effect of carvedilol on survival in severe chronic heart failure.
N Engl J Med, 334 (2001), pp. 1651-1658
[30.]
The, CAPRICORN., Investigators,.
Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction.
Lancet, 357 (2001), pp. 1385-1390
[31.]
A. Jánosi, J.K. Ghali, J. Herlitz, I. Czuriga, M. Klibaner, J. Wikstrand, A. Hjalmarson, On behalf of the MERIT-HF Study Group Budapest and Debrecen, Hungary, Shreveport, La, Göteborg and Mölndal, Sweden, and Wayne, Pa.
Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: Experiences from MERIT-HF.
Am Heart J, 146 (2003), pp. 721-728
[32.]
P.A. Poole-Wilson, K. Swedberg, J.G.F. Cleland, for the COMET investigators, et al.
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial.
Lancet, 362 (2003), pp. 7-13
[33.]
M. Romero, C.H. Arango.
Análisis de costo efectividad del uso de metoprolol succinato en el tratamiento de la hipertensión arterial y la falla cardiaca en Colombia.
Rev Colom Cardiol, 19 (2012), pp. 160-168
[34.]
S. Yusuf, S. Islam, C.K. Chow, S. Rangarajan, G. Dagenais, R. Diaz, On behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators, et al.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey.
Lancet, 378 (2011), pp. 1231-1243
Copyright © 2012. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular